verteporfin

(redirected from Benzoporphyrin)
Also found in: Wikipedia.

verteporfin

 [ver″tĕ-por´fin]
a photosensitizing agent that accumulates preferentially in neovasculature, including that in the choroid, such as occurs in age-related macular degeneration, ocular histoplasmosis, or pathologic myopia; the agent is then activated by light of a specific wavelength in the presence of oxygen, and causes local damage to the neovascular endothelium followed by vessel occlusion; it is administered intravenously prior to irradiation of the lesion with light from a compatible laser.

ver·te·por·fin

(vĕr-tē-pōr'fin),
Photosensitizer agent used in photodynamic therapy to treat choroidal neovascularization secondary to age related macular degeneration.

verteporfin

/ver·te·por·fin/ (ver″tĕ-por´fin) a photosensitizing agent that accumulates preferentially in neovasculature, including that in the choroid; used, together with appropriate laser irradiation of the lesion, in the treatment of neovascularization due to disciform macular degeneration, to presumed ocular histoplasmosis, or to pathologic myopia.

verteporfin

[ver′tĕ-por′fin]
a photosensitizing agent that accumulates preferentially in neovasculature, including that in the choroid, such as occurs in age-related macular degeneration, ocular histoplasmosis, or pathological myopia. The agent is then activated by light of a specific wavelength in the presence of oxygen and causes local damage to the neovascular endothelium followed by vessel occlusion. It is administered intravenously before irradiation of the lesion with light from a compatible laser.
References in periodicals archive ?
Four photosensitizing drugs, Photofring, Texas Red, a benzoporphyrin derivative monoacid (BPD), and lutetium texaphyrin (LuTex) were tested to see if they were substrates of the MDR-1 multidrug resistor pump, or if they could be used in PDT.
The new drug is called Benzoporphyrin derivative (BPD-MA Sverteporfin) and is being co-developed by QLT PhotoTherapeutics Inc.
QLT's second-generation product, Benzoporphyrin derivative (BPD-MA) is undergoing clinical trials for the treatment of age-related macular degeneration, the leading cause of blindness in the elderly.
QLT's second-generation product, Benzoporphyrin derivative (BPD-MA) is in Phase III clinical trials in North America and Europe for the treatment of age-related macular degeneration, the leading cause of blindness in the elderly.
The combination of ER-470 (EtNBS), a compound in development by Ergo Science Corporation, and BPD-MA, a benzoporphyrin derivative, produced a 95% reduction in average tumor weights compared with controls after activation by photoirradiation.
marketing rights to PHOTOFRIN(R), Benzoporphyrin derivative and additional light- activated compounds for cancerous and pre-cancerous indications.
In addition to PHOTOFRIN, the company has initiated clinical trials of its second-generation product, benzoporphyrin derivative, or BPD, as a potential treatment for non-melanoma skin cancer and psoriasis.
In a multi-center Phase I/II clinical trial, co-sponsored by QLT and CIBA Vision, researchers presented preliminary ocular safety and proof-of-principle data suggesting that the light-activated drug, Benzoporphyrin derivative (BPD), can selectively close abnormal blood vessels in the eye that are associated with the severe or "wet" form of Age-related Macular Degeneration (AMD) without causing vision loss associated with currently available treatments.
22 /PRNewswire/ -- Benzoporphyrin derivative (BPD), a light activated drug being developed by Quadra Logic Technologies Inc.
NASDAQ-NMS: QLTIF; Toronto, Vancouver: QLT) (QLT) announced today that it has begun a clinical trial of its proprietary light-activated drug, Benzoporphyrin derivative (also known as BPD), as a potential treatment for psoriasis.
Second, global development activities with CIBA Vision will be focused on completing clinical trials and securing marketing approvals for BPD (the company's second-generation drug, benzoporphyrin derivative, now in Phase II clinical trials) for the treatment of age-related macular degeneration.
Toronto, Vancouver: QLT) announced today that a clinical trial of the company's light-activated drug, Benzoporphyrin derivative (BPD), has commenced in Canada.